



BCRP knockout rat

Model	BCRP knockout rat
Strain	HsdSage: SD-Abcg2 ^{tm1Sage}
Location	U.S.
Availability	Live colony

Characteristics/husbandry

- + Background strain: Sprague Dawley
- + Biallelic 588 bp deletion within Abcg2 gene
- + Homozygous knockouts display total loss of protein via Western blot
- + Increased oral bioavailability of BCRP-specific substrates

Zygoty genotype

- + Homozygous

Research use

- + Neurotoxicology
- + DMPK efflux assay
- + Formulation blood brain barrier efflux
- + Drug-drug interactions
- + Tissue distribution
- + Efficacy assay

Origin

The Bcrp KO rat model was originally created at SAGE Labs, Inc. in St. Louis, MO and distributed out of the Boyertown, PA facility. The line continues to be maintained through the original SAGE Labs animal inventory acquired by Envigo.

Description


BCRP plays a protective role in neurotoxicity by limiting the efflux of xenobiotics into the brain. Homozygous null rats demonstrate increased exposure in the brain and plasma when dosed with BCRP-specific substrates. Loss of function of Bcrp leads to improper transport of drugs across epithelial cells and increased bioavailability of Bcrp substrates. This model is useful for studying metabolism of xenobiotic compounds, tissue distribution, DMPK, efficacy, formulation, and blood brain barrier efflux.

Citations

- 25868844 Bridges CC, Zalups RK, Joshee L. Toxicological significance of renal Bcrp: Another potential transporter in the elimination of mercuric ions from proximal tubular cells. *Toxicol Appl Pharmacol*. 2015 Jun 1;285(2):110-7.
- 25053619 Fuchs H, Kishimoto W, Gansser D, Tanswell P, Ishiguro N. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats. *Drug Metab Dispos*. 2014 Oct;42(10):1761-5.
- 29674491 Ganguly S, Panetta JC, Roberts JK, Schuetz EG. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice. *Drug Metab Dispos*. 2018 Jul;46(7):1014-1022
- 25539457 Huang L, Li X, Roberts J, Janosky B, Lin MH. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats. *Xenobiotica*. 2015;45(6):547-55
- 31331824 Kimura H, Yagi Y, Mikamo M, Maeda K, Kagawa S, Arimitsu K, Higashi T, Nishii R, Ono M, Nakamoto Y, Togashi K, Kusuhara H, Saji H. Evaluation of transporter-mediated hepatobiliary transport of newly developed 18F-labeled pitavastatin derivative, PTV-F1, in rats by PET imaging. *Drug Metab Pharmacokinet*. 2019 Oct;34(5):317-324
- 31685755 Miyake T. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats. *Biol Pharm Bull*. 2020 Mar 1;43(3):384-392.
- 31682973 Sato S, Tohyama K, Kosugi Y. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities. *Eur J Pharm Sci*. 2020 Jan 15;142:105119.
- 22711747 Zamek-Gliszczyński MJ, Bedwell DW, Bao JQ, Higgins JW. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. *Drug Metab Dispos*. 2012 Sep;40(9):1825-33.
- 23569176 Zamek-Gliszczyński MJ, Goldstein KM, Paulman A, Baker TK, Ryan TP. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics. *Drug Metab Dispos*. 2013 Jun;41(6):1174-8.



Figure 1: Dantrolene level of Bcrp (-/-) and wild type rats 2 hours after treatment (nM/g)




n = 3, 8-week old male Bcrp (-/-) and wild type Sprague Dawley rats

Figure 2: Oral absorption of sulfasalazine

Tissue	Bcrp (-/-) Mean	Wild Type Mean	Ratio of WT to KO
Brain Homogenate	16.0	3.3	0.2
Plasma	421	319	0.8

n= 2, 8-week old male Bcrp (-/-) and n=3 wild type littermates

Figure 3: Age/Weight/Curve chart



Contact us

North America 800.793.7287 gemsorders@envigo.com
 Envigo, 8520 Allison Pointe Blvd., Suite 400, Indianapolis, IN 46250, United States

